KR102583603B1 - Cd321 마커의 발현을 기반으로 한 순환 종양 세포의 검출, 정량 및/또는 단리 - Google Patents

Cd321 마커의 발현을 기반으로 한 순환 종양 세포의 검출, 정량 및/또는 단리 Download PDF

Info

Publication number
KR102583603B1
KR102583603B1 KR1020197030162A KR20197030162A KR102583603B1 KR 102583603 B1 KR102583603 B1 KR 102583603B1 KR 1020197030162 A KR1020197030162 A KR 1020197030162A KR 20197030162 A KR20197030162 A KR 20197030162A KR 102583603 B1 KR102583603 B1 KR 102583603B1
Authority
KR
South Korea
Prior art keywords
cells
marker
tumor
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030162A
Other languages
English (en)
Korean (ko)
Other versions
KR20190142330A (ko
Inventor
세드릭 블랑팡
파나지오타 소티로풀루
이브제니아 파츠쉔코
Original Assignee
유니베르시테 리브레 드 브룩크젤즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니베르시테 리브레 드 브룩크젤즈 filed Critical 유니베르시테 리브레 드 브룩크젤즈
Publication of KR20190142330A publication Critical patent/KR20190142330A/ko
Application granted granted Critical
Publication of KR102583603B1 publication Critical patent/KR102583603B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197030162A 2017-03-16 2018-03-16 Cd321 마커의 발현을 기반으로 한 순환 종양 세포의 검출, 정량 및/또는 단리 Active KR102583603B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161411.8 2017-03-16
EP17161411 2017-03-16
PCT/EP2018/056760 WO2018167312A1 (en) 2017-03-16 2018-03-16 Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker

Publications (2)

Publication Number Publication Date
KR20190142330A KR20190142330A (ko) 2019-12-26
KR102583603B1 true KR102583603B1 (ko) 2023-10-05

Family

ID=58387669

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030162A Active KR102583603B1 (ko) 2017-03-16 2018-03-16 Cd321 마커의 발현을 기반으로 한 순환 종양 세포의 검출, 정량 및/또는 단리

Country Status (8)

Country Link
US (2) US12123877B2 (enExample)
EP (2) EP4235179B1 (enExample)
JP (1) JP7278595B2 (enExample)
KR (1) KR102583603B1 (enExample)
AU (1) AU2018235021B2 (enExample)
CA (1) CA3054915A1 (enExample)
IL (1) IL269315B2 (enExample)
WO (1) WO2018167312A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019202788A1 (de) 2019-03-01 2020-09-03 Robert Bosch Gmbh Verfahren zum Zählen von Zelltypen oder Zellmarkern in einer Probe, insbesondere in einer Blutprobe
JP2020144054A (ja) * 2019-03-07 2020-09-10 学校法人昭和大学 末梢血循環癌細胞の検出方法及び検出装置
KR102654518B1 (ko) * 2020-05-26 2024-04-04 가톨릭대학교 산학협력단 Lsp1 결핍 t 세포
CN113009135B (zh) * 2021-02-19 2024-04-02 山东省大健康精准医疗产业技术研究院 一种检测cd47的管式磁微粒化学发光免疫定量试剂盒及其制备方法与应用
EP4405507A4 (en) * 2021-09-20 2025-11-05 Droplet Biosciences Inc METHODS FOR DISEASE ASSESSMENT USING A DRAINAGE FLUID

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130737A1 (en) 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
JP2007526761A (ja) * 2003-10-31 2007-09-20 ヴィタテックス， インコーポレイテッド 循環性の腫瘍細胞および内皮細胞の検出のための血液試験のプロトタイプおよび方法
WO2016118086A1 (en) * 2015-01-21 2016-07-28 Agency For Science, Technology And Research Column-based device and method for retrieval of rare cells based on size, and uses thereof
JP2017503488A (ja) * 2013-12-20 2017-02-02 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US8980568B2 (en) * 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
CA2628390A1 (en) * 2005-11-02 2007-05-18 The Regents Of The University Of Michigan Molecular profiling of cancer
CA2572530A1 (en) 2005-12-30 2007-06-30 Centocor, Inc. A method for determining the phenotype of cells
GB0808413D0 (en) 2008-05-09 2008-06-18 Univ Nottingham Stabilisation of blood cell conjugates
WO2010037134A2 (en) * 2008-09-29 2010-04-01 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
EP2199798A1 (en) 2008-12-18 2010-06-23 Universite Libre De Bruxelles Diagnostic method and kit of circulating tumor cells
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
US20130287790A1 (en) 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
GB2531881B (en) * 2013-02-02 2017-12-13 Univ Duke Method of isolating circulating tumor cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526761A (ja) * 2003-10-31 2007-09-20 ヴィタテックス， インコーポレイテッド 循環性の腫瘍細胞および内皮細胞の検出のための血液試験のプロトタイプおよび方法
WO2006130737A1 (en) 2005-06-02 2006-12-07 Immunivest Corporation A method for assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
JP2017503488A (ja) * 2013-12-20 2017-02-02 ザ ジェネラル ホスピタル コーポレイション 血中循環腫瘍細胞に関する方法およびアッセイ
WO2016118086A1 (en) * 2015-01-21 2016-07-28 Agency For Science, Technology And Research Column-based device and method for retrieval of rare cells based on size, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Justin D Lathia et al, Cell Reports (2014.), vol 6, no 1, pp 117-129.

Also Published As

Publication number Publication date
AU2018235021A1 (en) 2019-09-12
US20210190787A1 (en) 2021-06-24
EP3596467B1 (en) 2023-09-27
EP4235179A2 (en) 2023-08-30
IL269315B2 (en) 2025-05-01
IL269315A (en) 2019-11-28
EP3596467C0 (en) 2023-09-27
JP2020512549A (ja) 2020-04-23
CA3054915A1 (en) 2018-09-20
IL269315B1 (en) 2025-01-01
KR20190142330A (ko) 2019-12-26
EP4235179C0 (en) 2025-08-13
US20250027946A1 (en) 2025-01-23
EP3596467A1 (en) 2020-01-22
EP4235179B1 (en) 2025-08-13
EP4235179A3 (en) 2023-11-15
AU2018235021B2 (en) 2024-07-11
JP7278595B2 (ja) 2023-05-22
WO2018167312A1 (en) 2018-09-20
US12123877B2 (en) 2024-10-22

Similar Documents

Publication Publication Date Title
US20250027946A1 (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
RU2730984C1 (ru) Фармацевтическая композиция для лечения злокачественного новообразования
US8470542B2 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
JP2020122798A (ja) 抗ｌｉｌｒｂ抗体ならびにがんの検出及び処置におけるその使用
EP3802922B1 (en) Novel immune checkpoint inhibitors
CN103328500B (zh) 用于癌症的诊断和治疗的方法和化合物
JP2015525569A (ja) 修飾型自己エピトープに対する抗腫瘍免疫応答
AU2015206603A1 (en) Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
CA2990520C (en) Methods for detecting tissue infiltrating nk cells
Kondo et al. Detection of KK-LC-1 protein, a cancer/testis antigen, in patients with breast cancer
Yang et al. Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues
WO2006123829A1 (ja) ＰＡＰ２ａに対する抗体ならびにその診断的および治療的使用
WO2003024304A2 (en) Detection and treatment of cancers of the liver
WO2024119233A1 (en) Methods for diagnosing and treating ovarian cancer
Noordam et al. Expression of cancer testis antigens in tumor-adjacent normal liver predicts post-resection recurrence of Hepatocellular Carcinoma
WO2024083790A1 (en) Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
Galluzzi et al. An immunosurveillance mechanism controls cancer cell ploidy. Supplementary Material.
Zeinstra et al. Daniel den Hoed Cancer Center, Academic Hospital, Rotterdam, The Netherlands.
WO2013007801A1 (en) Predictive tool for response to anti-igf-1r antibody therapy in cancer patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601